• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Resilience Acquires Ology Bioservices

    RDIF, Hualan Ink COVID-19 Vaccine Deal

    Kintor, Visum Enter COVID-19 Manufacturing Partnership

    Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU

    Evotec Enters Master Service Agreement with Kazia Therapeutics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Resilience Acquires Ology Bioservices

    RDIF, Hualan Ink COVID-19 Vaccine Deal

    Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU

    Evotec Enters Master Service Agreement with Kazia Therapeutics

    Bristol Myers Squibb Expands at Cambridge Crossing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Quotient Sciences

    Adare Pharma Solutions

    Alcami

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    Reed-Lane

    Quotient Sciences

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Bioprocessing Trek

    Biosimilars are the next speed-bump for CMOs

    The Bioprocessing Trek
    Related CONTENT
    • Asymchem
    • Mogene
    • Softweb Solutions
    • Vetio Animal Health
    • Quality Metrics Feedback
    Emil W. Ciurczak, DoraMaxx Consulting09.16.19
    As larger pharmaceutical companies continue the reciprocal of mergers and acquisitions (M&A), namely divestitures and outsourcing, the pressure is on contract manufacturers to be at least as good as the company that developed the dosage form. That is because product developers are outsourcing production of proprietary products while they are still under patent protection. This means producing not a close imitation to a marketed product, which, I believe, is the definition of generic, but one which is identical, such that there is no difference in content, visual appearance, or performance.

    Making an “equivalent” to an existing small molecule product is difficult enough for a company not involved in its development, but when you include the provisions of the Question-based Review (QbR) Guidance, it becomes more arduous. The QbR for Generic Drugs: An Enhanced Pharmaceutical Quality Assessment System, has as one of its main thrusts requiring ANDAs (Amended New Drug Applications) from disparate companies follow a common form for style. Previously, when each of the large number of generic companies submitted their documents, each used their own internal style. This resulted in reviewers at the U.S. FDA having to navigate dozens of different types of applications, causing long wait times for the generics to get a yes/no answer on their new product’s fate. Imagine an English teacher allowing each student to write a term paper in his/her individual manner. The result would be chaos. This style requirement, alone, made the Guidance an excellent idea and, like a class receiving a term paper assignment, they all understood what was needed and in what order it should be presented. This did, indeed, speed up review times.

    Unfortunately, it also included some responsibilities for the generic company that were new to them. The responsibility for the purity of the product was extended to both earlier and later than had been the case previously. The existing responsibility was to “simply” produce a product, often covered by a monograph in the USP, that met the requirements of purity, assay, disintegration or dissolution times, and so on. Prior to QbR, it was sufficient to depend on the Certificate of Analysis (CoA) for purity, potency, etc. of an active pharmaceutical ingredient (API).

    But, under new Guidances for both FDA and ICH, the generic drug company, including contract manufacturing organizations (CMOs), now needs to ascertain the synthesis route for the API such that they can prove (validate) that their incoming RM testing and stability-indicating assays can identify and quantify any breakdown product from the synthesis of any of API, no matter the synthesis route by which they were produced. This extends to stability programs: each analysis method must be capable of finding and quantifying materials from the breakdown of the dosage form APIs.

    This means a constant feed-back loop between suppliers and the company’s labs, such that any analytical method can separate any and all potential by-products from synthesis and any and all break-down products from stability samples. Now, in a normal or traditional generic company or contract manufacturing facility, there are a number of trained analytical chemists, allowing the methods to morph to the specificity needed. It only adds a small amount of labor and time to the existing workload when small molecules are involved.

    However, when it comes to biological or biosimilar production and sales, all bets are off. Whether the CMO is producing a biological product that was the “original”—under contract to the patent-holder—or generating a product that is “similar,” the process is far more complicated than merely mixing powders and compressing a tablet or encapsulating the mix into a capsule. Understanding the effects of an API on the final dosage form is even covered in ICH Q11:

    “The identification of CQAs (critical quality attributes) for complex products can be challenging. Biotechnological/biological products, for example, typically possess such a large number of quality attributes that it might not be possible to fully evaluate the impact on safety and efficacy of each one. Risk assessments can be performed to rank or prioritize quality attributes. Prior knowledge can be used at the beginning of development and assessments can be iteratively updated with development data (including data from nonclinical and clinical studies) during the lifecycle. Knowledge regarding mechanism of action and biological characterization, such as studies evaluating structure-function relationships, can contribute to the assessment of risk for some product attributes.”

    This control/understanding of biologicals for the companies who have developed the drug is difficult enough, even with a large number of biochemists, molecular biologists, analytical and QC chemists. For smaller companies—both producers of the bioproducts and the generics who package them as dosage forms—largely used to performing small molecule analyses, this makes the task even more difficult. There are two levels of difficulty for a company to prepare to be able to produce and analyze biologically produced medicines:

    1. Previously Characterized Bio-Product
    This would be a biologically-produced drug substance, developed and patented by a major company and contracted to a CMO for production and distribution.
    • Even if all the preliminary analytical and process procedures are worked out by the initiator company, the CMO/generic will need to add analysts familiar with bioassays, purchase new equipment, and such. There will be a relatively small monetary outlay and time to full speed, assuming guidance by the parent company.
    • If the synthesis is done in-house, the facilities need to be expanded and more specialists added to staff. If the API is made by the CMO, all the necessary facilities need to be installed, unless they are already equipped for biosynthesis.
    2. New Synthesis Route for API or “Biosimilar”
    In this case, we still have the needs of analysts and analytical equipment for analyses, hardware and biochemists to make and purify the API, and all the equipment needed for example number one, plus the need to:
    • Isolate any and all byproducts from the expression and determine the effects of each, both short- and long-term, on patients. For example, if a strain of e coli was used to produce the protein. While the major component of the bioreaction may be “identical” to the patented entity, the secondary molecules are likely to be different.
    This will require a level of expertise above merely isolating and following the byproducts from a previously well-researched and characterized API. It will necessitate that the CMO either receives significant technical support from a larger (parent/client) company, or greatly expand its staff and equipment. For example, more stability ovens may be in order, as well as the chromatographs, mass spectrometers, and so forth, which will lead to staff increases to run this additional equipment.
    • Develop stability methodology to follow the major and minor components of the “biosimilar” to be able to track potential toxic effects. This requires considerable analytical development time and effort and would require biological testing of the short- and long-term effects in patients.

    This last point may be the most critical. When a small molecule is synthesized, the initial chemicals, in-process materials, and potential by-products are relatively simple to elucidate. This makes assay methods and evaluation of the results relatively straightforward. There are tests for carcinogenicity and mutagenicity available, and have been for decades, for small molecules. There are commonly used parameters for limits on breakdown products and impurities (USP, for example) for easily identified chemicals.

    With biological impurities, often proteins not seen previously, the stakes are potentially higher. Not only are there potential carcinogenicity and mutagenicity dangers, but, with unknown proteins, there are also potential immediate allergic reactions. Assuming there are no immediate reactions, there are potential long-term potential harmful effects, depending on the therapy for which the biological is being used. If the drug is a one-time application, such as heparin, there would not likely be a chance for the minor impurities to do much harm. On the other hand, long-term use of a bio-drug such as insulin, often used for decades, would allow even the smallest impurity the time to do harm to the patient.

    One might assume that a company that develops an NDE (new drug entity), based on a bioprocess, will spend years assessing potential harmful effects. A biosimilar would have, by definition, less time for any potential side-products to be evaluated before marketing. While the major active may be identical to the patented one, any biological process expresses numerous proteins, each particular to the mode of expression. When all is said and done—excluding potential lawsuits for patent-infringement, etc.—the most problematic feature of any biosimilar will be the exotic side products and potential side-effects.

    Considering the benefits to patients both therapeutic and financial, I truly wish that biosimilars can be produced safely. In any case, when contract manufacturers and/or generic companies embark on the bioprocessing trek, they will need to staff up with some experienced biochemists and such and do some bio-testing, if not their own clinical studies. But, in the end, the work is worth it.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • quality
    • apis
    • contract manufacturing organizations
    • Pharma
    Suggested For You
    Asymchem Asymchem
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Quality Metrics Feedback Quality Metrics Feedback
    FDA Extends CRADA with CluePoints FDA Extends CRADA with CluePoints
    Roche Wins Two Approvals for Cancer Drug Rozlytrek Roche Wins Two Approvals for Cancer Drug Rozlytrek
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing
    Merck to Build $650M Biomanufacturing Plant in NC Merck to Build $650M Biomanufacturing Plant in NC
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    06	Merck 06 Merck
    Re-Open Your Tool Chest Re-Open Your Tool Chest
    Syndax Pharma Gets IND Clearance for Leukemia Treatment Syndax Pharma Gets IND Clearance for Leukemia Treatment
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    Sierra’s Momelotinib Granted FDA Fast Track Designation Sierra’s Momelotinib Granted FDA Fast Track Designation

    Related Columns

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17

    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17


    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16

    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16


    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15

    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15


    • Biosimilars | Fill/Finish | QA/QC

      CMOs Are Willing to Pay for More Innovation

      Downstream improvements top the list
      Eric S. Langer, BioPlan Associates 09.11.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15

    • Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      Biosimilars and Their Future in Medicine

      The first step is understanding what biosimilars actually are
      Ben Locwin, Healthcare Science Advisors 06.02.15


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    • APIs | Biosimilars | Process Development | Supply Chain

      Biosimilars Improving Efficiency, Cost for All Biologics

      ...
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15

    Trending
    • Jubilant, Novavax Enter COVID-19 Vaccine Partnership
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement With EU
    • Resilience Acquires Ology Bioservices
    • Ensuring Pharma Manufacturing Quality
    • Sartorius Expands In The UK
    Breaking News
    • Resilience Acquires Ology Bioservices
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    • Kintor, Visum Enter COVID-19 Manufacturing Partnership
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU
    • Evotec Enters Master Service Agreement with Kazia Therapeutics
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Review Concludes Refined Grains Have a Place in Healthy Eating Patterns
    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    Coatings World

    Latest Breaking News From Coatings World

    SOS '21 Call For Papers
    ICP Acquiring Choice Adhesives
    PPG Brand Olympic Stains Announces 1st Ever 2021 Stain Color of the Year
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs Canon Medical's One-Beat Spectral Cardiac CT
    NeuroLogica Debuts Next-Generation SmartMSU with OmniTom Elite
    IZI Medical Products Launches Fully Automatic Quick-Core Auto Biopsy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Resilience Acquires Ology Bioservices
    RDIF, Hualan Ink COVID-19 Vaccine Deal
    Kintor, Visum Enter COVID-19 Manufacturing Partnership
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    2021 Perfumed Plume Awards Announces Finalists
    Bésame Cosmetics Unveils Marilyn Monroe Collection
    Procos Opens U.S. Office
    Happi

    Latest Breaking News From Happi

    Hair Luxury Company Expands Availability of Its Vegan Beauty to Walmart Online
    ACI Appoints Director, State Government Affairs
    Jergens Launches Mother’s Day Campaign
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Sakata INX and INX International continue sustainability efforts
    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Andritz to Supply Elliptical Cylinder Pre-Needler in France
    Ahlstrom-Munksjö to be Delisted from Nasdaq Stockholm
    Radienz Living Introduces Sustainable Products
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    AgNovos Healthcare's AGN1 LOEP SV Kit Obtains IDE
    First Surgeries Completed with Globus Medical's CREO ONE Robotic Screw
    BioMagnetic Sciences Names President and CEO
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI, Center for Automotive Research Collaborate
    Zebra Technologies Introduces New Alliance Track for PartnerConnect Channel Program
    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login